EcoDrugPlus

Histone Deacetylase 3

Ensembl ID : ENSATEG00000025701
Gene Symbol: HDAC3
3 Cross references
155 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSATEG00000011516
Gene Symbol: HDAC4
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 4-Like

Ensembl ID : ENSATEG00000018324
Gene Symbol: LOC113163766
3 Cross references
196 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSATEG00000011624
Gene Symbol: HDAC5
2 Cross references
195 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSATEG00000019652
Gene Symbol: HDAC6
2 Cross references
181 Possible Orthologues:

Histone Deacetylase 7-Like

Ensembl ID : ENSATEG00000024084
Gene Symbol: LOC113153725
2 Cross references
197 Possible Orthologues:

Histone Deacetylase 7a

Ensembl ID : ENSATEG00000003014
Gene Symbol: HDAC7A
2 Cross references
190 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSATEG00000014067
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2-Like

Ensembl ID : ENSATEG00000011839
Gene Symbol: LOC113151109
2 Cross references
232 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 4

Ensembl ID : ENSATEG00000002016
Gene Symbol: HCN4
2 Cross references
219 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSATEG00000021437
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSATEG00000020886
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).